Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
The authors describe the various available technologies used in orally disintegrating tablets.

Pharmaceutical Technology


1. FDA, CDER data standards manual (C-DRG-00201 Version 008), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071666.htm/, accessed Aug. 20, 2009.

2. FDA, Guidance for Industry: Orally Disintegrating Tablets (Rockville, MD, Dec. 2008), http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2007-D-0365-gdl.pdf, accessed Aug. 20, 2009.

3. European Pharmacopeia, Version 6.5, 2009.

4. EMEA, Committee for Medicinal Products for Human Use (CHMP), Reflection Paper: Formulations of Choice for the Paediatric Population, Adoption by CHMP Sept. 21, 2006, http://www.emea.europa.eu/pdfs/human/paediatrics/19481005en.pdf, accessed Aug. 20, 2009.

5. S. Freedman et al., "Oral Ondansetron for Gastroenteritis in a Pedatric Emergency Department," New Eng. J. of Med. 354 (16), 1698-1705 (2006).

6. R. Bohnacker et al., "Bestimmung der Zerfallszeit von Schmelztabletten mit Hilfe der Texture Analyser-Methode," Pharm. Ind. 67 (3), 327–335, (2005).

7. D. Gole et al., "Pharmaceutical and Other Dosage Forms," US patent 5,648,093, 1997.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here